Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
85% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. KPTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KPTI' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: 10000.00 Max: No Debt
Current: No Debt

Warning: Division by zero in /home/gurufocu/public_html/include/common_stock_functions_2.php on line 6548
N/A
No Debt
Equity to Asset 0.93
KPTI's Equity to Asset is ranked higher than
95% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. KPTI: 0.93 )
Ranked among companies with meaningful Equity to Asset only.
KPTI' s Equity to Asset Range Over the Past 10 Years
Min: -21.26  Med: 0.96 Max: 0.98
Current: 0.93
-21.26
0.98
Interest Coverage No Debt
KPTI's Interest Coverage is ranked higher than
68% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. KPTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KPTI' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 6.13
M-Score: 9.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -48215.00
KPTI's Operating margin (%) is ranked lower than
100% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. KPTI: -48215.00 )
Ranked among companies with meaningful Operating margin (%) only.
KPTI' s Operating margin (%) Range Over the Past 10 Years
Min: -33120.52  Med: -7778.08 Max: -2506.31
Current: -48215
-33120.52
-2506.31
Net-margin (%) -47942.92
KPTI's Net-margin (%) is ranked lower than
100% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. KPTI: -47942.92 )
Ranked among companies with meaningful Net-margin (%) only.
KPTI' s Net-margin (%) Range Over the Past 10 Years
Min: -33090.39  Med: -7777.69 Max: -2505.99
Current: -47942.92
-33090.39
-2505.99
ROE (%) -48.84
KPTI's ROE (%) is ranked lower than
88% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. KPTI: -48.84 )
Ranked among companies with meaningful ROE (%) only.
KPTI' s ROE (%) Range Over the Past 10 Years
Min: -53.44  Med: -47.67 Max: -41.9
Current: -48.84
-53.44
-41.9
ROA (%) -46.11
KPTI's ROA (%) is ranked lower than
90% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. KPTI: -46.11 )
Ranked among companies with meaningful ROA (%) only.
KPTI' s ROA (%) Range Over the Past 10 Years
Min: -372.3  Med: -42.56 Max: -40.03
Current: -46.11
-372.3
-40.03
ROC (Joel Greenblatt) (%) -3691.46
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. KPTI: -3691.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KPTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11974.25  Med: -9717.43 Max: -5061.86
Current: -3691.46
-11974.25
-5061.86
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

KPTI Guru Trades in

Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.50%)
Paul Tudor Jones Sold Out
» More
Q4 2014

KPTI Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.90
KPTI's P/B is ranked higher than
89% of the 706 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. KPTI: 0.90 )
Ranked among companies with meaningful P/B only.
KPTI' s P/B Range Over the Past 10 Years
Min: 0.9  Med: 4.64 Max: 10.64
Current: 0.9
0.9
10.64
P/S 791.46
KPTI's P/S is ranked lower than
99.99% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.72 vs. KPTI: 791.46 )
Ranked among companies with meaningful P/S only.
KPTI' s P/S Range Over the Past 10 Years
Min: 0  Med: 2513.50 Max: 4712
Current: 791.46
0
4712
Current Ratio 13.74
KPTI's Current Ratio is ranked higher than
94% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. KPTI: 13.74 )
Ranked among companies with meaningful Current Ratio only.
KPTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 16.96 Max: 47.98
Current: 13.74
0.49
47.98
Quick Ratio 13.74
KPTI's Quick Ratio is ranked higher than
94% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. KPTI: 13.74 )
Ranked among companies with meaningful Quick Ratio only.
KPTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 16.96 Max: 47.98
Current: 13.74
0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.09
KPTI's Price/Net Cash is ranked higher than
94% of the 201 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.02 vs. KPTI: 1.09 )
Ranked among companies with meaningful Price/Net Cash only.
KPTI' s Price/Net Cash Range Over the Past 10 Years
Min: 2.1  Med: 4.97 Max: 10.95
Current: 1.09
2.1
10.95
Price/Net Current Asset Value 1.07
KPTI's Price/Net Current Asset Value is ranked higher than
95% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. KPTI: 1.07 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KPTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.06  Med: 4.89 Max: 10.7
Current: 1.07
2.06
10.7
Price/Tangible Book 0.88
KPTI's Price/Tangible Book is ranked higher than
90% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.51 vs. KPTI: 0.88 )
Ranked among companies with meaningful Price/Tangible Book only.
KPTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.7  Med: 4.70 Max: 10.51
Current: 0.88
1.7
10.51
Earnings Yield (Greenblatt) (%) -1995.52
KPTI's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. KPTI: -1995.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KPTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -5912.29  Med: 0.00 Max: 0
Current: -1995.52
-5912.29
0

More Statistics

Revenue(Mil) $0
EPS $ -3.30
Short Percentage of Float30.22%
52-Week Range $5.25 - 35.65
Shares Outstanding(Mil)35.73

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 0 49
EPS($) -3.06 -3.02 -2.94 -2.49
EPS without NRI($) -3.06 -3.02 -2.94 -2.49

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:25K.Germany,
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
Karyopharm to Present at the Leerink Partners 5th Annual Global Healthcare Conference Feb 03 2016
5 Stocks Under $10 Set to Soar Jan 21 2016
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jan 20 2016
Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial in Multiple Myeloma Jan 19 2016
Karyopharm Initiates Second Generation SINE™ Compound Clinical Trial in Multiple Myeloma Jan 19 2016
Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma Jan 14 2016
Karyopharm Initiates Clinical Trial of Oral Selinexor in Advanced Liposarcoma Jan 14 2016
Karyopharm Therapeutics downgraded by Jefferies Jan 06 2016
Karyopharm to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Karyopharm to Present at the 34th Annual J.P. Morgan Healthcare Conference Jan 04 2016
Karyopharm Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 18 2015
Karyopharm Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : December 14,... Dec 14 2015
Traders Look to Upside - Comprehensive Research on 8x8 Inc., Lakeland Industries, Karyopharm... Dec 11 2015
KARYOPHARM THERAPEUTICS INC. Financials Dec 08 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Dec 08 2015
Karyopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination... Dec 07 2015
KARYOPHARM THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 07 2015
Karyopharm Therapeutics Presents Positive Clinical Data on the Activity of Selinexor in Combination... Dec 07 2015
Do Hedge Funds Love Karyopharm Therapeutics Inc (KPTI)? Dec 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK